INS and Abdominal obesity: In addition, the treatment of healthy people who are moderately overweight with GW501516 results in a significant reduction in fasting plasma insulin [392], and the dual PPARα/δ agonist GFT505 (elafibranor) improves hepatic and peripheral insulin sensitivity in men with abdominal obesity [393].